|From: klak32 (Rep: 24)||Date: 07/05/2019 09:12|
|Forum: Wall Street Pit - Msg #2792728 - List TYME msgs ||Thread #674089549 (Rec: 0) |
|The biotechnology company developing cancer metabolism based therapies said Friday its Phase II TYME-88-Panc study evaluating SM-88 in patients with advanced pancreatic cancer continues to demonstrate encouraging results and a well-tolerated safety profile. |
SM-88 demonstrated median overall survival of 6.4 months as of April 25, the company said. Efficacy indicators showed strong correlation with greater overall survival. These indicators included achieving stable disease or better and decreases in circulating tumor cells, Tyme said.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.